{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:37:51Z","timestamp":1792553871907,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["HL006007"],"award-info":[{"award-number":["HL006007"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jtct.2025.02.021","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T16:40:42Z","timestamp":1740415242000},"page":"305-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell Disease"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-4138","authenticated-orcid":false,"given":"Zaina","family":"Inam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Jeffries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wynona","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Luckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald","family":"Phang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triscia","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffani","family":"Farrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Tisdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-6615","authenticated-orcid":false,"given":"Matthew M.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jtct.2025.02.021_bib0001","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2025.02.021_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211046559","article-title":"Hematopoietic stem cell transplant for sickle cell disease: patient selection and timing based on sickle cell-related multiple chronic conditions","volume":"30","author":"Jang","year":"2021","journal-title":"Cell Transplant."},{"issue":"7","key":"10.1016\/j.jtct.2025.02.021_bib0003","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17474086.2018.1486703","article-title":"Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced","volume":"11","author":"Leonard","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.021_bib0004","doi-asserted-by":"crossref","first-page":"47.e1","DOI":"10.1016\/j.jtct.2022.10.012","article-title":"Long-term organ function after HCT for SCD: a report from the Sickle Cell Transplant Advocacy and Research Alliance","volume":"29","author":"Stenger","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2025.02.021_bib0005","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/17474086.2023.2268271","article-title":"Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease","volume":"16","author":"Inam","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"17","key":"10.1016\/j.jtct.2025.02.021_bib0006","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.021_bib0007","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jtct.2025.02.021_bib0008","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1083-8791(03)00192-7","article-title":"Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia","volume":"9","author":"Iannone","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"10.1016\/j.jtct.2025.02.021_bib0009","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.021_bib0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"issue":"8","key":"10.1016\/j.jtct.2025.02.021_bib0011","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.021_bib0012","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.02.021_bib0013","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3389\/fimmu.2020.01791","article-title":"Chimerism in the realm of hematopoietic stem cell transplantation for non-malignant disorders-a perspective","volume":"11","author":"Zimmerman","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jtct.2025.02.021_bib0014","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1097\/TXD.0000000000001179","article-title":"ABO mismatch in allogeneic hematopoietic stem cell transplant: effect on short- and long-term outcomes","volume":"7","author":"Valentini","year":"2021","journal-title":"Transplant Direct"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.021_bib0015","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41409-020-01124-6","article-title":"Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question","volume":"56","author":"Marco-Ayala","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.021_bib0016","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17311","article-title":"Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres","volume":"192","author":"Alzahrani","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2025.02.021_bib0017","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2021-144454","article-title":"Nonmyeloablative HLA-identical sibling donor transplantation for children and young adults with sickle cell disease: interim results of the SUN multicenter phase II trial","volume":"138","author":"Nickel","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jtct.2025.02.021_bib0018","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/jcm11133856","article-title":"Across the myeloablative spectrum: hematopoietic cell transplant conditioning regimens for pediatric patients with sickle cell disease","volume":"11","author":"Limerick","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.021_bib0019","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.bbmt.2019.02.011","article-title":"Nonmyeloablative matched sibling donor hematopoietic cell transplantation in children and adolescents with sickle cell disease","volume":"25","author":"Guilcher","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.021_bib0020","first-page":"187","article-title":"Mixed donor chimerism following stem cell transplantation for sickle cell disease","volume":"30","author":"Shah","year":"2023","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.02.021_bib0021","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3324\/haematol.2019.227561","article-title":"Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy","volume":"105","author":"Magnani","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jtct.2025.02.021_bib0022","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/1042819022386833","article-title":"Sickle cell anemia and hematological neoplasias","volume":"43","author":"Paydas","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jtct.2025.02.021_bib0023","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0141076816651037","article-title":"Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study","volume":"109","author":"Seminog","year":"2016","journal-title":"J R Soc Med"},{"issue":"13","key":"10.1016\/j.jtct.2025.02.021_bib0024","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2025.02.021_bib0025","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.2022017960","article-title":"Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism","volume":"140","author":"Lawal","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.02.021_bib0026","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.22.01203","article-title":"Secondary neoplasms after hematopoietic cell transplant for sickle cell disease","volume":"41","author":"Eapen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.021_bib0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.jtct.2025.02.021_bib0028","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.021_bib0029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41591-021-01650-w","article-title":"Long-term outcomes of lentiviral gene therapy for the beta-hemoglobinopathies: the HGB-205 trial","volume":"28","author":"Magrin","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.021_bib0030","first-page":"322","article-title":"ABO blood grouping mismatch in hematopoietic stem cell transplantation and clinical guides","volume":"12","author":"Shokrgozar","year":"2018","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"12","key":"10.1016\/j.jtct.2025.02.021_bib0031","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bbmt.2005.07.015","article-title":"ABO blood group barrier in allogeneic bone marrow transplantation revisited","volume":"11","author":"Seebach","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.021_bib0032","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3324\/haematol.2016.160804","article-title":"Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT","volume":"102","author":"Canaani","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.021_bib0033","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbmt.2014.12.036","article-title":"ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation","volume":"21","author":"Logan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"S2","key":"10.1016\/j.jtct.2025.02.021_bib0034","first-page":"e30977","article-title":"Impact of pre-HSCT RBC alloimmunization on post-HSCT outcomes in pediatric patients with SCD. Abstract. Plenary Paper #2001 presented at: 2024 ASPHO Conference","volume":"71","author":"Inam","year":"2024","journal-title":"Pediatr Blood Cancer"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T17:28:23Z","timestamp":1746898103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725010553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2666636725010553"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.02.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell Disease","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}